Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:48:27 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:MRNS from 2023-05-03 to 2024-05-02 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 08:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
2024-04-15 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
2024-04-05 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-03-27 08:41U:MRNSNews ReleaseMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review
2024-03-05 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at Upcoming Investor Conferences
2024-02-20 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2024-02-16 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-04 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-04 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY ‚ ® Net Product Revenue and Provides Business Update
2023-12-07 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-20 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
2023-11-14 16:05U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-07 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-07 07:00U:MRNSNews ReleaseMarinus Pharmaceuticals Initiates Global Access Program for ZTALMY ‚ ® (ganaxolone) Oral Suspension CV
2023-10-24 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
2023-10-06 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-09-21 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
2023-09-12 16:00U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
2023-09-06 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-08-17 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
2023-08-11 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-08-10 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-07-27 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
2023-07-13 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-06-21 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
2023-06-02 16:30U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-05-26 08:10U:MRNSNews ReleaseMarinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY ‚ ® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
2023-05-17 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
2023-05-11 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
2023-05-09 16:01U:MRNSNews ReleaseMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-05-03 07:01U:MRNSNews ReleaseMarinus Pharmaceuticals to Present at Upcoming Investor Conferences